Please sign in to follow a disease.
Bronchiolitis obliterans syndrome
MONDO:0015265A lung disorder that is mainly associated with chronic allograft dysfunction after lung transplantation and that is characterized by inflammation and fibrosis of bronchiolar walls that reduce the diameter of the bronchioles and result in progressive and irreversible airflow obstruction.
Also known as: BOOP, constrictive bronchiolitis, organised pneumonia, organized pneumonia, bronchiolitis obliterans with obstructive pulmonary disease, BO, bronchiolitis exudativa, bronchiolitis obliterans
103 clinical trials for this condition and its sub-types, 42 tagged with Bronchiolitis obliterans syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Bronchiolitis obliterans syndrome
-
New drug may help lung damage after stem cell transplants
Disease control OngoingThis study tests a new oral drug called alvelestat (MPH966) in adults who have lung damage (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block an enzyme that may cause lung injury. The trial has two parts: first to find the safest and most eff…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Blood-filtering therapy may slow lung decline in transplant patients
Disease control OngoingThis phase 3 trial tests a treatment called extracorporeal photopheresis (ECP) for lung transplant patients who develop bronchiolitis obliterans syndrome (BOS), a form of chronic rejection. ECP involves filtering a patient's blood, treating it with a light-sensitive drug, and ret…
Phase 3 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a cancer drug help lung damage after transplant?
Disease control OngoingThis phase 2 study tests the drug ruxolitinib (Jakafi) in 50 people who developed bronchiolitis obliterans syndrome (BOS) after a stem cell transplant. BOS is a serious lung condition that causes scarring and breathing problems. The goal is to see if ruxolitinib can improve lung …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Could faulty stem cells in the airways drive a rare lung disease? a study aims to find out.
Knowledge-focused CancelledThis study explores whether stem cell dysfunction in the small airways causes bronchiolitis obliterans syndrome (BOS), a serious lung condition that can occur after a stem cell transplant. Researchers will collect airway cells from people with BOS and healthy volunteers to compar…
Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can a simple home breathing test catch lung trouble early in transplant patients?
Knowledge-focused OngoingThis study follows 250 people who have had a donor stem cell transplant to see if respiratory viruses lead to a lung condition called bronchiolitis obliterans syndrome (BOS). Participants use a handheld device at home to measure lung function and provide nasal swabs and blood sam…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Lung transplant patients followed for years to uncover Long-Term health secrets
Knowledge-focused By invitation onlyThis study follows 4,000 people who have had a lung transplant to see how their lungs and overall health change over many years. Researchers will collect data from clinic visits, lung function tests, and surveys about daily activities and quality of life. The goal is to better un…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Gene clues may explain why light therapy helps some transplant patients
Knowledge-focused OngoingThis study looks at gene activity in blood cells from 30 kidney or lung transplant patients who have chronic rejection. Researchers want to find out why some patients improve with a treatment called extracorporeal photoapheresis (ECP) while others do not. The goal is to better un…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC